#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Current systemic treatment of metastatic prostate cancer


Authors: M. M. Heck;  H. Kübler;  J. E. Gschwend;  M. Retz
Published in: Urol List 2015; 13(1): 8-12

Overview

In patients with advanced, metastastic prostate cancer systemic therapy is indicated. At initial diagnosis, these patients are treated with androgen-deprivation therapy in order to lower androgen-levels at castration-level. This treatment initially can be combined with docetaxel chemotherapy, especially in patients with higher tumor burden. If prostate cancer progresses despite adequate castration level of androgens, we speak of castration-resistant prostate cancer. In the background of rapidly evolving new treatment options for castration-resistant prostate cancer - namely abiraterone, enzalutamide, cabazitaxel, radium-223-dichloride - the approval criteria and side-effect profile have to be taken into account. The following article summarizes curent systemic treatment options for metastatic hormone-naïve and castration-resistant prostate cancer.

Key words:
metastatic castration-resistant prostate cancer, docetaxel, abiraterone, enzalutamide, cabazitaxel, radium-223-dichloride, chemohormonal therapy


Sources

1. Heidenreich A, Bastian PJ, Bellmunt J et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant pros­tate cancer. Eur Urol 2014; 65(2): 467–479. doi: 10.1016/j.eururo.2013.11.002.

2. Sweeney C, Chen YH, Carducci MA et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. J Clin Oncol 2014; 32 (5 Suppl): LBA2.

3. Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368(2): 138–148. doi: 10.1056/NEJMoa1209096.

4. Rathkopf DE, Smith MR, de Bono JS et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol 2014; 66(5): 815–825. doi: 10.1016/j.eururo.2014.02.056.

5. Beer TM, Armstrong AJ, Rathkopf DE et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371(5): ­424–433. doi: 10.1056/NEJMoa1405095.

6. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351(15): 1513–1520.

7. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351(15): 1502–1512.

8. Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T et al. 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol 2013; 14(2): 117–124. doi: 10.1016/S1470-2045(12)70537-5.

9. Parker C, Nilsson S, Heinrich D et al. Alpha emit­ter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369(3): 213–223. doi: 10.1056/NEJMoa1213755.

10. Parker C, Coleman RE, Nilsson S et al. Updated survival, quality of life (QOL) and safety data of ra­dium-223 chloride (RA-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases from the phase 3 double-blind, randomized, multinational study (ALSYMPCA). Ann Oncol 2012; 23: ix294.

11. Di Lorenzo G, Buonerba C, Faiella A et al. Phase II study of docetaxel re-treatment in docetaxel-pre­treated castration-resistant prostate cancer. BJU Int 2011; 107(2): 234–239. doi: 10.1111/j.1464-410X.2010.09498.x.

12. Heck MM, Thalgott M, Retz M et al. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer. BJU Int 2012; 110(11 Pt B): E635–E640. doi: 10.1111/j.1464-410X.2012.11364.x.

13. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progres­sing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376(9747): 1147–1154. doi: 10.1016/S0140-6736(10)61389-X.

14. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364(21): ­1995–2005. doi: 10.1056/NEJMoa1014618.

15. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367(13): 1187–1197.

Labels
Paediatric urologist Urology
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#